Can You Take Semaglutide with a Normal BMI?

What the STEP 1 trial enrolled, and what it tells us about BMI thresholds

The evidence base for Wegovy starts with the STEP programme. In the pivotal STEP 1 trial published in the New England Journal of Medicine, participants had a mean BMI of around 37.9 kg/m², comfortably within the obese range. Average weight loss over 68 weeks at the 2.4mg maintenance dose was roughly 15%. That is a meaningful result, but it is drawn from a population with significant excess weight and the associated metabolic burden. The trial was not designed to test what semaglutide does in people with a healthy weight, and the results cannot be extrapolated to that group. Regulatory bodies do not license medicines based on speculation; they license them based on the populations actually studied. So when the MHRA approved Wegovy for adults with a BMI of 30 or above (or 27 with a qualifying condition), it was because that is the evidence the manufacturer submitted, not a bureaucratic fence drawn at random. Taking any prescription medicine outside its licensed indication carries unknown risk, and for a GLP-1 receptor agonist that slows gastric emptying and suppresses appetite, the consequences in someone who does not have significant excess weight have simply not been studied at scale.

Why BMI alone is not the whole picture, especially near the boundary

BMI is a screening tool, not a diagnosis. It can underestimate fat mass in people who carry weight centrally, and it is blind to visceral fat, metabolic markers and body composition. That is why the Wegovy licence includes the 27–29.9 corridor for people with at least one weight-related condition. Someone at BMI 28 with confirmed hypertension and pre-diabetes sits within the licensed population; someone at BMI 28 with no qualifying conditions does not. If your BMI is close to 27, it is worth exploring who can take semaglutide in detail, because the answer turns on the presence of those comorbidities rather than a single number. Ethnic background also matters. For South Asian, Chinese, Middle Eastern, Black African and African-Caribbean adults, UK guidance lowers both thresholds by 2.5 kg/m², so a BMI of 24.5 with a qualifying condition could bring someone into the licensed range. The full eligibility picture is explored on our BMI requirements for semaglutide page. What this means practically: BMI 24.9 feels close to 25, but the clinical and legal position is clear, a normal BMI, without the ethnic-background adjustment and without a qualifying condition, sits outside the licence.

The position on NHS access and private prescribing for normal-BMI patients

On the NHS, the bar is higher still. NICE's appraisal of Wegovy (TA875) restricts it to adults with a BMI of 35 or above (32.5 for the ethnic-background groups mentioned above) and at least one weight-related comorbidity, within specialist services, for a maximum of two years. Someone with a normal BMI cannot access Wegovy through the NHS under any current pathway. Private prescribing follows the licensed indication too, a GPhC-registered Independent Prescriber cannot issue a private prescription for a use that falls outside what the MHRA has licensed the medicine for, and doing so would breach professional standards. That is why any online service claiming to offer semaglutide to people with a healthy weight should be treated with serious scepticism. For context on what private treatment involves for people who do qualify, our Wegovy cost page covers what a legitimate prescription includes. If you are unsure whether your BMI and health history might qualify you, the starting point is a clinical consultation rather than a self-assessment.

If your BMI is in the normal range: what are the options?

If your BMI genuinely falls below 25 and you have no qualifying conditions, semaglutide is not a clinically or legally appropriate route. That is a frustrating answer if you feel you would benefit, but it reflects where the safety evidence exists. What a prescriber can do is help you understand whether any factors in your health history shift the picture, a recently confirmed diagnosis, a change in metabolic markers, or an ethnic-background threshold adjustment that you had not considered. Our clinical team, led by our clinical director, review every consultation personally; they are well placed to look at the full clinical picture rather than a single number. For people who do sit within the licensed BMI range and are weighing up their options, our Wegovy overview explains how the treatment works and what starting it involves. And if your question is specifically about the 25–26.9 range with a possible qualifying condition, the dedicated pages on BMI 25 and BMI 26 go into more depth. For those who do qualify, speaking to our prescribers is the right next step. Treatment (if approved) is dispensed by our GPhC-registered pharmacy (registration 9012878), dispatched the same day and delivered by DPD in plain, unbranded packaging, tracked to your door.